Duloxetine for Chronic Depression: a Double-blind Study
Dysthymic Disorder, Depressive Disorder NOS
About this trial
This is an interventional treatment trial for Dysthymic Disorder focused on measuring dysthymia, dysthymic disorder, chronic depression, chronic low-grade depression, atypical depression, minor depression, depression NOS, depression, depressive disorder, mood disorder, unipolar depression, low-grade depression
Eligibility Criteria
Inclusion Criteria: age 20 to 75 years (ages 20 to 60 for MRI sub-study) diagnosis of dysthymic disorder (chronic depression) or depression NOS minimum of 2 years duration of current episode of depression Exclusion Criteria: current major depression diagnoses including delirium, dementia, bipolar disorder, schizophrenia substance abuse or dependence in the past 6 months pregnant or nursing women serious risk of suicide
Sites / Locations
- New York State Psychiatric Institute
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
duloxetine (cymbalta)
Placebo treatment
Duloxetine medication: a medication currently marketed in the USA that is reported to have pharmacological effects including reuptake blockage for serotonin and norepinephrine
placebo treatment: treatment with placebo capsules that match active medication capsules